Business Support · Founded 2021 · www.sagilityhealth.com · BSE 544282 · NSE SAGILITY · ISIN INE0W2G01015
No Notes Added Yet
Here's a structured overview of Sagility Ltd.:
Important Note regarding Ticker:
Sagility Ltd. was formed from the healthcare services business of Hinduja Global Solutions (HGS) which was acquired by Baring Private Equity Asia (now EQT Private Equity Asia) in 2021. As such, Sagility Ltd. is currently a privately held company under the ownership of EQT Private Equity Asia and does not trade publicly under the ticker "SAGILITY" on Indian exchanges or elsewhere. This analysis will proceed based on Sagility Ltd. as a privately held entity focused on healthcare BPM services.
1. Business Overview
Sagility Ltd. is a global leader in healthcare business process management (BPM) and digital transformation services. The company partners with healthcare payers, providers, and pharmacy benefits managers (PBMs) to optimize their operations, enhance customer experience, and drive digital innovation. Sagility provides a comprehensive suite of services including back-office support, claims processing, member enrollment, provider data management, clinical process management, customer service, and technology solutions like automation and AI. Its core business model revolves around long-term service contracts, leveraging its deep domain expertise and global delivery capabilities (primarily from India) to provide cost-effective and specialized solutions. Sagility makes money by charging fees for these services, helping clients reduce costs, improve efficiency, and navigate complex healthcare regulations.
2. Key Segments / Revenue Mix
Sagility primarily serves the healthcare sector across three main client segments:
Payers: Health insurance companies, managed care organizations, and government healthcare programs. Services include claims administration, member services, enrollment, and compliance.
Providers: Hospitals, clinics, physician groups, and other healthcare facilities. Services include revenue cycle management, patient engagement, and clinical support.
Pharmacy Benefits Managers (PBMs): Companies that manage prescription drug benefits for health plans. Services involve formulary management, claims processing, and patient support.
While specific revenue contributions per segment are not publicly disclosed for the privately held entity, the company's focus is holistic, offering end-to-end solutions across these key areas of the healthcare ecosystem.
3. Industry & Positioning
Sagility operates within the highly specialized and competitive global healthcare BPM and IT services industry. This industry is characterized by increasing demand for digital transformation, cost optimization, and regulatory compliance among healthcare organizations worldwide. Key drivers include aging populations, rising healthcare costs, and evolving regulatory landscapes (especially in the US, which is a major market for healthcare BPM).
Sagility positions itself as a specialized, domain-focused player within this industry. It competes with:
Large, diversified IT services firms: Companies like TCS, Wipro, Infosys, HCLTech, and Cognizant, which have large healthcare verticals.
Other specialized healthcare BPO providers: Niche players focused exclusively on healthcare.
Sagility differentiates itself through its deep understanding of healthcare processes, regulatory expertise, and ability to deliver integrated technology-enabled solutions. It leverages India's talent pool for cost-effective delivery while focusing on value-added services.
4. Competitive Advantage (Moat)
Sagility possesses several competitive advantages:
Specialized Domain Expertise: Deep knowledge of complex healthcare regulations (e.g., HIPAA in the US), clinical processes, and industry-specific workflows creates high barriers to entry for generalist providers.
Switching Costs: Once a service provider is integrated into a client's core operational processes (e.g., claims processing, revenue cycle management), switching to a new vendor can be expensive, disruptive, and risky due to data migration, process re-engineering, and compliance concerns.
Client Relationships: Long-standing relationships with key healthcare payers and providers build trust and recurring revenue streams.
Global Delivery Model: Leveraging a skilled talent pool in India and other locations allows for cost-effective service delivery, providing a competitive pricing advantage.
5. Growth Drivers
Key factors that can drive Sagility's growth over the next 3-5 years include:
Digital Transformation in Healthcare: Increasing adoption of automation, AI, analytics, and cloud solutions by healthcare organizations to improve efficiency and patient outcomes.
Cost Containment Pressures: Healthcare clients constantly seek to reduce operational costs, driving outsourcing and process optimization.
Regulatory Complexity: Evolving healthcare policies and compliance requirements necessitate specialized expertise that companies like Sagility can provide.
Expansion of Services: Opportunities to upsell and cross-sell new digital and analytics services to existing clients and expand into new sub-segments within healthcare.
Geographic Expansion: Potential for growth in new markets beyond its current primary focus areas.
Aging Global Population: Drives increasing demand for healthcare services, which in turn fuels demand for supporting BPM functions.
6. Risks
Sagility faces several key business risks:
Client Concentration: Dependence on a few large healthcare clients for a significant portion of its revenue can pose a risk if a major contract is lost or reduced.
Regulatory Changes: Significant changes in healthcare policy (especially in the US) could impact client demand, operational requirements, and profitability.
Talent Attrition & Wage Inflation: Intense competition for skilled professionals in India and other delivery locations can lead to higher wage costs and difficulty retaining talent.
Technological Disruption: Failure to continuously innovate and adapt to rapidly evolving technologies (e.g., generative AI, advanced analytics) could erode its competitive edge.
Data Security & Compliance Breaches: Handling sensitive protected health information (PHI) exposes the company to severe reputational and financial damage from data breaches or non-compliance.
Intense Competition: The industry is highly competitive, potentially leading to pricing pressures and margin erosion.
Currency Fluctuations: As a company with significant global revenues and costs, it is exposed to foreign exchange rate volatility, particularly USD-INR movements.
7. Management & Ownership
Sagility Ltd. is owned by EQT Private Equity Asia (formerly Baring Private Equity Asia), a prominent global private equity firm. The management team typically comprises experienced professionals from the IT and BPM services industry, often with a strong background in healthcare. Under private equity ownership, the management is usually focused on driving operational efficiency, strategic growth initiatives, and preparing the company for a potential future exit (e.g., an IPO or sale). The ownership structure by EQT suggests a focus on value creation, leveraging strategic investments in technology, talent, and market expansion.
8. Outlook
Sagility benefits from a robust and growing healthcare BPM market, driven by secular trends in digital transformation, cost optimization, and regulatory demands. Its specialized focus within healthcare provides a defensible niche, supported by high switching costs and deep domain expertise. The backing of EQT Private Equity Asia typically implies strategic investments aimed at accelerating growth and operational excellence.
However, the company operates in a highly competitive environment. Managing client concentration risk, staying ahead of rapid technological advancements, and navigating evolving healthcare regulations will be crucial. Talent retention and wage inflation pressures in key delivery geographies also pose ongoing challenges. The outlook suggests continued growth, contingent on effective execution of its digital transformation strategy and successful management of competitive and operational risks within its specialized healthcare niche.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1260 | 1283 | 1223 | 1325 | 1453 | 1568 | 1539 | 1658 | 1971 | 2024 |
| Other Income | 6 | 5 | 24 | 15 | 44 | 10 | 10 | 58 | 8 | 25 |
| Total Income | 1266 | 1288 | 1248 | 1340 | 1497 | 1579 | 1549 | 1717 | 1980 | 2049 |
| Total Expenditure | 1000 | 976 | 1029 | 1024 | 1061 | 1195 | 1193 | 1243 | 1460 | 1540 |
| Operating Profit | 266 | 312 | 218 | 316 | 436 | 383 | 356 | 473 | 520 | 509 |
| Interest | 47 | 43 | 37 | 30 | 30 | 30 | 27 | 25 | 25 | 22 |
| Depreciation | 176 | 176 | 110 | 126 | 116 | 114 | 118 | 122 | 124 | 124 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -33 | 0 |
| Profit Before Tax | 44 | 93 | 71 | 160 | 290 | 239 | 210 | 327 | 339 | 363 |
| Provision for Tax | -27 | 13 | 49 | 43 | 73 | 56 | 62 | 76 | 71 | 105 |
| Profit After Tax | 71 | 80 | 22 | 117 | 217 | 183 | 149 | 251 | 268 | 258 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 71 | 80 | 22 | 117 | 217 | 183 | 149 | 251 | 268 | 258 |
| Adjusted Earnings Per Share | 0.4 | 0.2 | 0 | 0.3 | 0.5 | 0.4 | 0.3 | 0.5 | 0.6 | 0.6 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 923 | 4218 | 4754 | 5570 | 7192 |
| Other Income | 21 | 18 | 31 | 56 | 101 |
| Total Income | 944 | 4236 | 4784 | 5626 | 7295 |
| Total Expenditure | 734 | 3191 | 3668 | 4272 | 5436 |
| Operating Profit | 211 | 1045 | 1116 | 1354 | 1858 |
| Interest | 65 | 215 | 185 | 127 | 99 |
| Depreciation | 147 | 644 | 689 | 467 | 488 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -33 |
| Profit Before Tax | -2 | 186 | 242 | 760 | 1239 |
| Provision for Tax | 3 | 42 | 13 | 221 | 314 |
| Profit After Tax | -5 | 144 | 228 | 539 | 926 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -5 | 144 | 228 | 539 | 926 |
| Adjusted Earnings Per Share | -0 | 0.7 | 0.5 | 1.2 | 2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 17% | 82% | 0% | 0% |
| Operating Profit CAGR | 21% | 86% | 0% | 0% |
| PAT CAGR | 136% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 3% | NA% | NA% | NA% |
| ROE Average | 7% | 5% | 4% | 4% |
| ROCE Average | 10% | 7% | 5% | 5% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 4027 | 6207 | 6443 | 8336 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 4184 | 2324 | 1665 | 567 |
| Other Non-Current Liabilities | 989 | 942 | 969 | 925 |
| Total Current Liabilities | 885 | 1056 | 1452 | 1089 |
| Total Liabilities | 10085 | 10529 | 10529 | 10917 |
| Fixed Assets | 8621 | 8607 | 8667 | 8997 |
| Other Non-Current Assets | 58 | 129 | 142 | 99 |
| Total Current Assets | 1406 | 1793 | 1720 | 1821 |
| Total Assets | 10085 | 10529 | 10529 | 10917 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 374 | 585 | 344 |
| Cash Flow from Operating Activities | -32 | 857 | 973 | 1214 |
| Cash Flow from Investing Activities | -7714 | -129 | -469 | -964 |
| Cash Flow from Financing Activities | 8116 | -545 | -751 | -256 |
| Net Cash Inflow / Outflow | 370 | 183 | -247 | -6 |
| Closing Cash & Cash Equivalent | 374 | 585 | 344 | 344 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.02 | 0.75 | 0.53 | 1.15 |
| CEPS(Rs) | 0.74 | 4.11 | 2.14 | 2.15 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -13.92 | -2.56 | 15.04 | 17.54 |
| Core EBITDA Margin(%) | 20.53 | 24.35 | 22.83 | 23.3 |
| EBIT Margin(%) | 6.86 | 9.49 | 8.98 | 15.93 |
| Pre Tax Margin(%) | -0.2 | 4.4 | 5.08 | 13.65 |
| PAT Margin (%) | -0.51 | 3.4 | 4.8 | 9.68 |
| Cash Profit Margin (%) | 15.44 | 18.68 | 19.3 | 18.06 |
| ROA(%) | -0.05 | 1.39 | 2.17 | 5.03 |
| ROE(%) | 0 | 0 | 7.67 | 7.36 |
| ROCE(%) | 0.77 | 4.78 | 5.06 | 10.14 |
| Receivable days | 366.1 | 86.3 | 86.38 | 80.21 |
| Inventory Days | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 | 37.29 |
| Price/Book(x) | 0 | 0 | 0 | 2.45 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 6.2 | 0.87 | 1.23 | 3.69 |
| EV/Core EBITDA(x) | 27.21 | 3.5 | 5.25 | 15.19 |
| Net Sales Growth(%) | 0 | 356.83 | 12.69 | 17.17 |
| EBIT Growth(%) | 0 | 532.12 | 6.57 | 107.89 |
| PAT Growth(%) | 0 | 3173.69 | 58.99 | 136.18 |
| EPS Growth(%) | 0 | 3179.42 | -28.81 | 116.29 |
| Debt/Equity(x) | -1.57 | -4.73 | 0.3 | 0.1 |
| Current Ratio(x) | 1.59 | 1.7 | 1.18 | 1.67 |
| Quick Ratio(x) | 1.59 | 1.7 | 1.18 | 1.67 |
| Interest Cover(x) | 0.97 | 1.86 | 2.31 | 6.98 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.04 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 82.39 | 82.39 | 67.38 | 67.38 | 50.95 | 50.95 |
| FII | 3.78 | 3.39 | 5.99 | 5.59 | 10.25 | 10.02 |
| DII | 7.25 | 7.48 | 14.06 | 14.88 | 21.36 | 22.29 |
| Public | 6.58 | 6.74 | 12.58 | 12.15 | 17.44 | 16.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 385.71 | 385.71 | 315.41 | 315.41 | 238.51 | 238.51 |
| FII | 17.67 | 15.87 | 28.02 | 26.19 | 47.98 | 46.92 |
| DII | 33.92 | 35 | 65.83 | 69.64 | 100 | 104.34 |
| Public | 30.82 | 31.55 | 58.88 | 56.89 | 81.64 | 78.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 468.13 | 468.13 | 468.13 | 468.13 | 468.13 | 468.13 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +17% | +82% | — | — |
| Operating Profit CAGR | +21% | +86% | — | — |
| PAT CAGR | +136% | — | — | — |
| Share Price CAGR | +3% | — | — | — |
| ROE Average | +7% | +5% | +4% | +4% |
| ROCE Average | +10% | +7% | +5% | +5% |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 82.39 | 82.39 | 67.38 | 67.38 | 50.95 | 50.95 |
| FII | 3.78 | 3.39 | 5.99 | 5.59 | 10.25 | 10.02 |
| DII | 7.25 | 7.48 | 14.06 | 14.88 | 21.36 | 22.29 |
| Public | 17.61 | 17.61 | 32.62 | 32.62 | 49.05 | 49.05 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 385.71 | 385.71 | 315.41 | 315.41 | 238.51 | 238.51 |
| FII | 17.67 | 15.87 | 28.02 | 26.19 | 47.98 | 46.92 |
| DII | 33.92 | 35 | 65.83 | 69.64 | 100 | 104.34 |
| Public | 82.42 | 82.42 | 152.72 | 152.72 | 229.62 | 229.62 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 468.13 | 468.13 | 468.13 | 468.13 | 468.13 | 468.13 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.